UK-based immuno-oncology company IGEM – a spin-out of King’s College London – has appointed Dr Tim Wilson as its new chief executive officer at a time when the company has raised £2m from Epidarex Capital, in order to progress its pipeline of IgE antibody drug candidates.
Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity research.
He said: “The raising of £2m in series A finding is a testament to the compelling research results generated by Dr Karagiannis and her team at King’s College London.
“I look forward to leading the company as we create important new therapies for the treatment of cancer.”
Wilson has worked for numerous private and public life science companies in the US and Europe at all stages of development, from start-ups to industry leaders.
Dr Peter Finan, venture partner and Epidarex Capital, said: “We are very pleased to have been able to recruit Dr Tim Wilson to lead IGEM as CEO.
“We look forward to working with IGEM to realise their potential.”